Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Earnings for Relmada Therapeutics, Inc. (RLMD)
Earnings in 2023 (TTM): $-98,791,746
According to Relmada Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-98,791,746. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Relmada Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-98,791,746 | $-98,791,746 |
| 2022 | $-157,043,823 | $-157,043,823 |
| 2021 | $-125,751,809 | $-125,751,809 |
| 2020 | $-59,456,394 | $-59,456,394 |
| 2019 | $-15,005,198 | $-15,005,198 |
| 2018 | $-17,318,060 | $-17,318,060 |
| 2017 | $-8,960,852 | $-8,960,852 |
| 2016 | $-6,286,521 | $-6,286,521 |
| 2015 | $-2,974,691 | $-2,974,691 |
| 2014 | $-20,803,596 | $-20,803,596 |
| 2013 | $-45,015 | $-45,015 |
| 2012 | $-12,052 | $-12,052 |